GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (NAS:OCUL) » Definitions » Effective Interest Rate on Debt %

Ocular Therapeutix (Ocular Therapeutix) Effective Interest Rate on Debt %

: 19.96% (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Ocular Therapeutix's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $16.60 Mil. Ocular Therapeutix's average total debt for the quarter that ended in Dec. 2023 was $83.20 Mil. Therefore, Ocular Therapeutix's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 19.96%.


Ocular Therapeutix Effective Interest Rate on Debt % Historical Data

The historical data trend for Ocular Therapeutix's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.50 11.49 11.36 11.39 15.36

Ocular Therapeutix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Effective Interest Rate on Debt % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.92 10.97 12.31 18.55 19.96

Competitive Comparison

For the Biotechnology subindustry, Ocular Therapeutix's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix Effective Interest Rate on Debt % Distribution

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Effective Interest Rate on Debt % falls into.



Ocular Therapeutix Effective Interest Rate on Debt % Calculation

Ocular Therapeutix's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -11.338/( (64.283+83.389)/ 2 )
=-1  *  -11.338/73.836
=15.36 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=62.684 + 1.599
=64.283

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=81.803 + 1.586
=83.389

Ocular Therapeutix's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  -16.604/( (83.018+83.389)/ 2 )
=-1  *  -16.604/83.2035
=19.96 %

where

Total Debt  (Q: Sep. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=81.14 + 1.878
=83.018

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=81.803 + 1.586
=83.389

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Ocular Therapeutix  (NAS:OCUL) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Ocular Therapeutix Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix (Ocular Therapeutix) Business Description

Industry
Traded in Other Exchanges
Address
24 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Executives
Summer Road Llc 10 percent owner 207 6TH STREET, WEST PALM BEACH FL 33401
Antony C. Mattessich director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Rabia Gurses Ozden officer: Chief Medical Officer C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
Philip C. Strassburger officer: General Counsel 24 CROSBY DRIVE, BEDFORD MA 01730
Donald Notman officer: Chief Financial Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Christopher G White officer: Chief Business Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Jeffrey S. Heier director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patricia Kitchen officer: Chief Operations Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Leslie J. Williams director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Seung Suh Hong director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Amarpreet Sawhney director, 10 percent owner, officer: President and CEO C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730